|
2.5 Etiologie - Gènes
|
|
|
|
2.6 Etiologie - Environnement
|
|
|
|
4.9 Dép., diag. & prono. - Sein
|
|
|
|
5.2 Pharma
|
|
|
|
CTI heads to the FDA with its Baxalta-partnered cancer drug [FierceBiotech]
|
|
|
|
|
|
The
drug, partnered with Baxalta, is a kinase inhibitor called pacritinib
that is designed to treat the rare bone marrow malignancy myelofibrosis.
In Phase III results disclosed earlier this year, pacritinib met its
main goal by reducing spleen volume by 35% or more in myelofibrosis
patients, reversing a deadly effect of the disease
|
|
|
|
|
|
|
|
|
|
5.2.3 Pharma - économie
|
|
|
Shkreli, Turing, and PhRMA [In the Pipeline]
|
|
|
|
|
|
By
wrapping ourselves in statements of purpose and noble intentions, we in
the R&D-driven part of the drug industry are doing ourselves a
disservice. It leaves us unable to distinguish ourselves from obnoxious
parasites, outfits like Turing that can, with a straight face, recite
the same rationales.
|
|
|
|
|
|
|
5.3 Traitements - FDA, EMA,...
|
|
|
|
5.4 Traitements - Economie
|
|
|
The price isn’t right, but neither is the effect [The Cancer Blog]
|
|
|
|
|
|
At
the upcoming European Cancer Congress, a study by a UK pharmacologist
on how much it costs to make cancer drugs such as imatinib (Glivec) will
reveal that Americans in particular are paying hugely more than the
manufacturing cost, but Western European prices are also high.
|
|
|
|
|
|
|
NICE says yes to new class of drug for adults with leukaemia [NICE]
|
|
|
|
|
|
The
decision follows a preliminary decision earlier this year where NICE
asked for the company to provide further information on the cost
effectiveness of the drug. Gilead Sciences responded by submitting new
economic analyses alongside a simple discount agreement to the list
price of idelalisib.
|
|
|
|
|
|
|
|
How Prescription Drugs Get So Wildly Expensive [WIRED]
|
|
|
|
|
|
Perceived
value is complicated (it’s economics, after all), but for drugs it
pretty much boils down to three things: How many patients the drug will
treat, how many similar drugs are on the market, and how much a drug
improves a patient’s life.
|
|
|
|
|
|
|
|
5.6 ESMO
|
|
|
|
|
|
6. Lutte contre les cancers
|
|
|
|
|
|
6.1 Observation
|
|
|
|
6.6 Publications
|
|
|
|
|
6.7 DMP, Big Data & applis
|
|
|
ASCO Applauds IOM Report "Improving Diagnosis in Health Care" [ASCO]
|
|
|
|
|
|
We
are particularly encouraged by IOM’s recommendation to require health
IT vendors, by 2018, to meet standards for interoperability among
different health IT systems so that effective, efficient, and structured
flow of patient information across care settings can be supported.
|
|
|
|
|
|
|
6.7.2 Applis
|
|
|
Do we need to rethink regulation for health apps? [PHG Foundation]
|
|
|
|
|
|
Although
the “quality, safety, or efficacy” of health apps are vital to
determine and regulate, there is another side to the control of these
apps that the BMJ article does not expand on: the impact they might have
on the delivery of healthcare more generally, and how that might need
to be managed.
|
|
|
|
|
|
|
6.9 Controverses
|
|
|
Parents of Ashya King put him at risk, report says [The Guardian]
|
|
|
|
|
|
Last
year in the wake of Ashya’s case, a group of leading child cancer
doctors wrote to NHS England’s chief executive, Simon Stevens, to
express concerns that other families would reject NHS advice and demand
treatment abroad which could reduce children’s chances of survival.
|
|
|
|
|
|